Literature DB >> 12464525

Decreased amplitudes in multiple sclerosis patients with normal visual acuity: a VEP study.

R Diem1, A Tschirne, M Bähr.   

Abstract

Primary demyelination with relative preservation of axons is considered to be one pathological hallmark of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. However, imaging and pathomorphological studies have stimulated a recent re-emergence of interest in the axonal, neurodegenerative aspect of MS pathology. Axonal injury appears to be a key factor of disability and permanent neurological deficit in MS patients. In the present electrophysiological study, visual potentials evoked by pattern reversal (VEPs) were recorded in 25 MS patients with normal visual acuity and unimpaired visual functions. Compared to a control population, VEP amplitudes for two different spatial frequencies were significantly decreased. From this observation, we conclude that an underlying pathological process threatening axonal integrity may not be reliably reflected by clinical parameters due to the distinct ability of the visual system to compensate for axonal loss. Pattern VEP may thus serve as an objective tool to diagnose and to monitor axonal pathology in MS. Focal conduction block due to demyelination as a cause for reduced VEP amplitudes can not be fully excluded, but would appear less likely since latency prolongation in the MS group was moderate compared to controls.

Entities:  

Mesh:

Year:  2003        PMID: 12464525     DOI: 10.1016/s0967-5868(02)00172-8

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

1.  Roles of Treg/Th17 Cell Imbalance and Neuronal Damage in the Visual Dysfunction Observed in Experimental Autoimmune Optic Neuritis Chronologically.

Authors:  Yuanyuan Liu; Caiyun You; Zhuhong Zhang; Jingkai Zhang; Hua Yan
Journal:  Neuromolecular Med       Date:  2015-08-30       Impact factor: 3.843

2.  Diagnostic value of visual evoked potentials for clinical diagnosis of multiple sclerosis.

Authors:  Niphon Chirapapaisan; Sawarin Laotaweerungsawat; Wanicha Chuenkongkaew; Patthanee Samsen; Ngamkae Ruangvaravate; Atiporn Thuangtong; Nacha Chanvarapha
Journal:  Doc Ophthalmol       Date:  2014-10-21       Impact factor: 2.379

3.  Attention and memory dysfunctions in mild multiple sclerosis.

Authors:  Michael Tinnefeld; Friederike H Treitz; Claus G Haase; Hans Wilhelm; Irene Daum; Pedro M Faustmann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-01-07       Impact factor: 5.270

4.  Retinal nerve fibre layer thinning in patients with clinically isolated optic neuritis and early treatment with interferon-beta.

Authors:  Kurt-Wolfram Sühs; Katharina Hein; Jens R Pehlke; Barbara Käsmann-Kellner; Ricarda Diem
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

Review 5.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

6.  Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.

Authors:  Chelsea M Larabee; Yang Hu; Shruti Desai; Constantin Georgescu; Jonathan D Wren; Robert C Axtell; Scott M Plafker
Journal:  Mol Vis       Date:  2016-04-11       Impact factor: 2.367

7.  Neuroprotection by eIF2α-CHOP inhibition and XBP-1 activation in EAE/optic neuritiss.

Authors:  Haoliang Huang; Linqing Miao; Feisi Liang; Xiaodong Liu; Lin Xu; Xiuyin Teng; Qizhao Wang; William H Ridder; Kenneth S Shindler; Yang Sun; Yang Hu
Journal:  Cell Death Dis       Date:  2017-07-20       Impact factor: 8.469

8.  Regulation of myelin structure and conduction velocity by perinodal astrocytes.

Authors:  Dipankar J Dutta; Dong Ho Woo; Philip R Lee; Sinisa Pajevic; Olena Bukalo; William C Huffman; Hiroaki Wake; Peter J Basser; Shahriar SheikhBahaei; Vanja Lazarevic; Jeffrey C Smith; R Douglas Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-29       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.